MDGL

303.49

5.17% 14.91

Handel nachbörslich: 303.49

Madrigal Pharmaceuticals Inc (MDGL)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt MDGL? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$288.58

Offen:

$290.25

24-Stunden-Volumen:

466.41K

Relative Volume:

1.27

Marktkapitalisierung:

$6.54B

Einnahmen:

Nettoeinkommen (Verlust:

$-518.67M

KGV:

-15.77

EPS:

-19.24

Netto-Cashflow:

$-438.32M

1W Leistung:

-10.65%

1M Leistung:

+41.53%

6M Leistung:

+37.91%

1J Leistung:

+71.79%

1-Tages-Spanne:

$288.80

$308.43

1-Wochen-Bereich:

$272.72

$342.58

52-Wochen-Spanne:

$168.25

$368.29

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

Firmenname

Madrigal Pharmaceuticals Inc

Sektor

Healthcare (1196)

Branche

Biotechnology (683)

Telefon

404-380-9263

Adresse

200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA

Mitarbeiter

376

Twitter

@MadrigalPharma

Nächster Verdiensttermin

2024-10-31

Neueste SEC-Einreichungen

MDGL's Discussions on Twitter

Vergleichen Sie MDGL mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
MDGL	303.49	6.54B	0	-518.67M	-438.32M	-19.24
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2022-12-20	Bestätigt	Oppenheimer	Outperform
2022-12-19	Bestätigt	H.C. Wainwright	Buy
2022-12-19	Bestätigt	Piper Sandler	Overweight
2022-12-19	Hochstufung	Raymond James	Underperform → Mkt Perform
2022-07-08	Herabstufung	B. Riley Securities	Buy → Neutral
2021-10-07	Eingeleitet	Jefferies	Buy
2021-08-06	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2021-05-20	Fortgesetzt	Goldman	Buy
2020-11-24	Fortgesetzt	Evercore ISI	Outperform
2020-11-06	Bestätigt	H.C. Wainwright	Buy
2020-07-31	Eingeleitet	Piper Sandler	Overweight
2020-06-05	Eingeleitet	BMO Capital Markets	Market Perform
2020-05-05	Eingeleitet	Chardan Capital Markets	Buy
2020-01-30	Eingeleitet	Canaccord Genuity	Buy
2020-01-09	Hochstufung	UBS	Neutral → Buy
2019-11-07	Bestätigt	H.C. Wainwright	Buy
2019-06-25	Eingeleitet	Stifel	Hold
2019-06-10	Hochstufung	B. Riley FBR	Neutral → Buy
2019-02-28	Bestätigt	H.C. Wainwright	Buy
2019-02-22	Eingeleitet	SVB Leerink	Outperform
2019-01-23	Eingeleitet	UBS	Neutral
2018-12-14	Eingeleitet	Wolfe Research	Outperform
2018-12-12	Eingeleitet	B. Riley FBR	Neutral
2018-11-19	Herabstufung	Raymond James	Mkt Perform → Underperform
2018-11-16	Hochstufung	Evercore ISI	In-line → Outperform
2018-09-04	Eingeleitet	Citigroup	Buy
2018-08-06	Herabstufung	Goldman	Buy → Neutral
2018-06-28	Eingeleitet	Raymond James	Mkt Perform

Alle ansehen

Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten

05:01 AM

(11/18/24) MDGL: A Promising Play in the Weight Loss Drug Space - Moneyshow.com

05:01 AM

Nov 16, 2024

Madrigal Pharmaceuticals gains amid takeover speculation - MSN

Nov 16, 2024

Nov 15, 2024

John Paulson's Strategic Acquisition in Madrigal Pharmaceuticals - GuruFocus.com

Nov 15, 2024

Janus Henderson Group PLC's Strategic Reduction in Madrigal Phar - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

RTW INVESTMENTS, LP Expands Stake in Madrigal Pharmaceuticals Inc - GuruFocus.com

Nov 14, 2024

Nov 13, 2024

(MDGL) Trading Report - Stock Traders Daily

Nov 13, 2024

Nov 11, 2024

Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar And Theravance - Barchart

Nov 11, 2024

Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance - Yahoo Finance

Nov 11, 2024

Nov 10, 2024

1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More - AOL

Nov 10, 2024

Nov 09, 2024

Fiera Capital Corp Sells 3,535 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat

Nov 09, 2024

Madrigal Pharmaceuticals director Richard Levy sells $1.75 million in stock By Investing.com - Investing.com Canada

Nov 09, 2024

Madrigal Pharmaceuticals director Richard Levy sells $1.75 million in stock - Investing.com India

Nov 09, 2024

Nov 07, 2024

Madrigal Pharmaceuticals (FRA:YDO1) Current Ratio : 5.98 (As of Sep. 2024) - GuruFocus.com

Nov 06, 2024

Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences - The Manila Times

Nov 06, 2024

Madrigal Pharmaceuticals to Present at Three Major Healthcare Investor Conferences | MDGL Stock News - StockTitan

Nov 06, 2024

Analysts Offer Predictions for MDGL Q1 Earnings - MarketBeat

Nov 06, 2024

Nov 05, 2024

Madrigal Pharmaceuticals director Richard Levy sells $1.5m in shares - Investing.com

Nov 05, 2024

Madrigal Pharmaceuticals director Richard Levy sells $1.5m in shares By Investing.com - Investing.com UK

Nov 05, 2024

Non-Alcoholic Steatohepatitis Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal - Barchart

Nov 05, 2024

B. Riley Forecasts Strong Price Appreciation for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock - MarketBeat

Nov 05, 2024

MDGL (Madrigal Pharmaceuticals) Change In Receivables : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 05, 2024

Nov 04, 2024

Check Out What Whales Are Doing With MDGL - Benzinga

Nov 04, 2024

Madrigal Stock Soars 23% as NASH Drug Rezdiffra Crushes Expectat - GuruFocus.com

Nov 04, 2024

Madrigal Pharmaceuticals (NASDAQ:MDGL) Reaches New 1-Year High After Analyst Upgrade - MarketBeat

Nov 04, 2024

Madrigal Stock Soars 23% as NASH Drug Rezdiffra Crushes Expectations - Yahoo Finance

Nov 04, 2024

FY2028 Earnings Forecast for MDGL Issued By Leerink Partnrs - MarketBeat

Nov 04, 2024

Emerald Advisers LLC Has $5.79 Million Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - MarketBeat

Nov 04, 2024

Nov 03, 2024

Apple Satellite Connectivity Provider Globalstar And Timberland Parent V.F Corp Are Among Top 7 Mid Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio? - Benzinga

Nov 03, 2024

Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion - Seeking Alpha

Nov 03, 2024

Nov 02, 2024

(MDGL) Long Term Investment Analysis - Stock Traders Daily

Nov 02, 2024

Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH - Yahoo Finance

Nov 02, 2024

Forecast: Analysts Think Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) Business Prospects Have Improved Drastically - Simply Wall St

Nov 02, 2024

Analysts Just Made A Notable Upgrade To Their Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Forecasts - Yahoo Finance

Nov 02, 2024

Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up - MSN

Nov 02, 2024

Madrigal Pharmaceuticals Announces Strong Q3 2024 Results and Strategic Advances - MSN

Nov 02, 2024

Nov 01, 2024

MDGL stock soars to 52-week high, reaching $299.99 By Investing.com - Investing.com South Africa

Nov 01, 2024

Madrigal Pharma Stock Soars Despite Novo Nordisk’s ‘Superior’ MASH Trial Results: Retail Bullish On Earnings Beat - MSN

Nov 01, 2024

Novo's Wegovy Isn't A 'Silver Bullet' For MASH. Madrigal Rockets. - Investor's Business Daily

Nov 01, 2024

Madrigal Pharmaceuticals stock jumps on MASH drug hopes - Yahoo Finance

Nov 01, 2024

Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Raised to $441.00 - MarketBeat

Nov 01, 2024

Madrigal Pharmaceuticals (NASDAQ:MDGL) Releases Earnings Results, Beats Expectations By $2.02 EPS - MarketBeat

Nov 01, 2024

MDGL stock soars to 52-week high, reaching $299.99 - Investing.com

Nov 01, 2024

Madrigal Pharmaceuticals (NASDAQ:MDGL) Sees Strong Trading Volume Following Earnings Beat - MarketBeat

Nov 01, 2024

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q3 2024 Earnings Call Transcript - MSN

Nov 01, 2024

Regeneron battles Wall Street uncertainty; Madrigal extends fast launch of MASH drug - Yahoo Finance

Nov 01, 2024